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Background: Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) and interchange of hospital-associated strains carrying the
staphylococcal chromosomal cassette mec-II (SCCmec-II) with those in the community (SCCmec-IV) has increased. This study assesses the
impact of MRSA and different MRSA types on clinical outcomes, medication use, and antibiotic sensitivities.
Methods:MRSA isolates from CF patients at our center were typed by SCCmec- and pvl status. Patient characteristics, lung function and nutrition
are compared between MRSA types and to age, gender and Pseudomonas aeruginosa matched patients with chronic methicillin sensitive S. aureus
(MSSA) infection.
Results: Seventy-two percent of patients carry pvl negative SCCmec-II isolates. Seventeen percent of all MRSA were SCCmec-IV pvl positive
(USA300). These patients were younger and fewer had chronic P. aeruginosa infection, whereas pvl-negative SCCmec-IV isolates show highest
antibiotic resistance. Nutritional outcomes and FEV1 percent predicted (75.1±2.7 versus 77.9±2.7) did not differ in patients with MRSA
compared to those with MSSA but MRSA patients received more pulmonary maintenance but not oral antibiotic medications.
Conclusion: Patients with chronic MRSA are treated more intensely than age, gender and Pseudomonas aeruginosa matched MSSA-positive
patients but clinical characteristics within MRSA patients vary depending on MRSA types.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Methicillin resistant Staphylococcus aureus (MRSA); Medication use; Molecular typing; Outcome1. Introduction
Staphylococcus aureus (S. aureus) is one of the most
frequent organisms in CF patients in the US with a prevalence
of 45% in infants to children two years of age and peaking
around 62% in school age children [1,2]. In recent years there
has been a steep increase in the proportion of S. aureus isolates
that are methicillin resistant (MRSA) from 2% in 2001 to 21.2%
in 2007 per CFF Annual Patient-Registry-Report (http://www.
cff.org/). Although prevalence in most European countries is⁎ Corresponding author. Tel.: +1 919 966 1055; fax: +1 919 966 6179.
E-mail address: Marianne_Muhlebach@med.unc.edu (M.S. Muhlebach).
1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2011.02.004much lower there has been an increase in MRSA during this
time frame.
MRSA, initially described in the 1960s only in hospital
settings, has spread in frequency within and outside the
healthcare environment. Infection with MRSA in previously
healthy subjects i.e., community-associated MRSA (CA-
MRSA) was originally described in the 1980s as causing
complicated skin infections and necrotizing pneumonia. In the
US one particular strain, USA300 has been especially
successful [3]. So-called healthcare-associated MRSA (HA-
MRSA) and CA-MRSA differ in several aspects other than time
of contact between the patient and the healthcare system (http://
cdc.gov/ncidod/dhqp/ar_mrsa_ca.html). Methicillin resistance
is mediated by production of low-affinity penicillin bindingd by Elsevier B.V. All rights reserved.
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the staphylococcal chromosomal cassette mec (SCCmec). To
date five different SCCmec types have been described, and of
these, SCCmec types I, II, and III are typically healthcare-
associated strains in the US. These SCCmec strains carry
additional resistance genes making them resistant to many
classes of antibiotics. Conversely, CA-MRSA typically harbor
the smaller SCCmec types IV or V carrying only mecA-
mediated resistance resulting in susceptibility to a wider variety
of antibiotic classes.
Studies performed prior to the recent spike in MRSA showed
either no or controversial impact of MRSA on clinical outcomes
in CF [4,5]. More recent epidemiologic studies show varying
effects of MRSA on clinical outcomes. A cross-sectional study
including CF patients with S. aureus as the sole organism
showed that those with MRSA had lower lung function than
those with MSSA [6]. Using the same database Sawicki et al.
found that longitudinal decline in lung function was worse in
patients with MRSA, however both, before and after acquisition
of this pathogen [7]. Using the CFF Registry Dasenbrook et al.
showed a more rapid decline in lung function in adolescents
who acquired MRSA compared to those who remained MRSA
negative in a 10-year cohort study; however no effect was seen
in adults acquiring MRSA [8]. Most recently a higher mortality
risk in patients with chronic MRSA infection was shown [9].
While there is increasing concern for a negative impact of
MRSA none of these studies examined the potential impact of
different MRSA strains, the effect and intensity of therapy that
patients receive, and if different SCCmec types affect antibiotic
sensitivities.
In this study we hypothesize that infection with CA-MRSA
versus HA-MRSA is associated with different patient char-
acteristics in CF and antibiotic susceptibilities. Further we
compare treatment intensity and outcomes in patients with
MRSA to an age, gender and P. aeruginosa status matched
methicillin sensitive S. aureus (MSSA) patient group.2. Methods
2.1. Patients
Patients with MRSA were selected based on prospective
collection of all MRSA positive respiratory secretions obtained
from CF patients seen at the UNC Pediatric and Adult CF
clinics between October 2005 and October 2007 [10]. One
isolate per patient was included but previous and subsequent
microbiological data were tracked to confirm that the patient
had chronic MRSA carriage (≥3MRSA positive cultures/year).
Patients with chronic MSSA infection were selected to be the
same gender, age within 0.5 years, and have the same
Pseudomonas status (see Clinical data) as the matched MRSA
subject.
Diagnosis of CF had been confirmed per standard recom-
mendations [11]. Approval to perform this research using a
waiver to obtain consent was obtained from our Institutional
Review Board.2.2. Clinical data
P. aeruginosa infection status was classified into three
categories (never, intermittent and chronic) based on Leeds
criteria, with the modification of including mucoid phenotype
in the definition given the negative impact of mucoid
P. aeruginosa on lung function [12,13].
Pulmonary function was measured at each clinic visit per
standard clinical protocol using Sensormedics spirometer and
was expressed as percent of predicted normal values [14,15].
For children b8 years old, preschool specific equations were
used [16,17]. Use of oral antibiotics, routine medications and
number of exacerbations (IV and orally treated) were extracted
from clinic notes and in some cases from PortCF. For
longitudinal data analyses lung function results were down-
loaded from the CF Foundation Patient Registry data at our
center (PortCF).
2.3. Microbiology methods
Respiratory samples were processed per routine methodol-
ogies for CF specimens [18]. Detection of MRSA was based on
growth on mannitol salt agar followed by a positive tube
coagulase test or a positive BactiStaph latex agglutination test
(Remel, Lenexa, KS). Screening tests were performed using
oxacillin screening agar and full susceptibility testing was done
by Kirby–Bauer disk diffusion following CLSI guidelines [19].
Molecular methods used to determine PVL status and SCCmec
type were performed as previously described [10].
2.4. Statistical methods
Statistical analyses were performed using SAS® Version 9.2
(SAS, Cary, NC). Cross-sectional comparisons were performed
using t-tests for continuous variables and chi-squared tests for
categorical variables.
For longitudinal analyses mixed linear models were fit to
repeated measurements of FEV1 and BMI that appropriately
accounted for randomly missing observations and correlations
among the repeated measurements on a given patient [20]. Age
at time of infection and gender were included as model
covariates.
Two sets of mixed linear models were fit to address two
different hypotheses. One set included separate intercepts and
slopes for MRSA and MSSA patients and assumed a constant
linear trend across the two-year period surrounding the time of
infection. The second set of models allowed for the slopes to
differ between the months prior to infection and the months
following infection. This second set of models allowed testing
for an effect for change in FEV1 at the time of infection.
3. Results
3.1. MRSA isolates and molecular characterization
One-hundred and twentyMRSA isolates from distinct patients
were collected over a 2 year period, which is representative of our
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2 years later showed persistence of the same molecular strain
within a given patient, consistent with our prior findings [10].
After exclusion of patient samples with insufficient information
(n=11), transplant recipients (n=11), or variable appearance of
MRSA andMSSA (n=16) eighty-two pediatric and adult patients
were included in further analyses.
Bacterial isolates of 58 patients were positive for SCCmec-II
and one patient for SCCmec-III; thus, SCCmec types usually
associated with healthcare-associated infections in the US were
present in ~72% (n=59) of patients and all were pvl negative.
Isolates from 23 patients (28%) carried the SCCmec-IV MRSA;
of these 14 isolates were also pvl positive; thus 17% of all
MRSA were SCCmec-IV pvl positive, and further character-
ization showed these to be USA300 strains [10].
Clinical characteristics of all MRSA positive patients and
MRSA types are summarized in Table 1. Patients with pvl-
positive SCCmec-IVMRSA strains were younger than those with
SCCmec-II (p=0.039), but not those with pvl negative SCCmec-
IV (p=0.063). The younger age of patients with pvl positive
SCCmec-IV strains is likely a result of the increased spread of
USA300 strain in recent years. The time of initial positiveMRSA
culture could be determined for 62 patients. Duration of MRSA
infection was longer for patients harboring SCCmec-II strains
(5.0±0.8 years, n=42) compared to the seven patients with pvl-
positive SCCmec-IV strains (1.8±0.4 years, p=0.005) but not the
13 patients with pvl-negative SCCmec-IV strains (2.1±0.5 years,
p=0.075).
Prevalence and type of P. aeruginosa were significantly
higher in patients with SCCmec-II strains compared to patients
with SCCmec-IV (86.4% versus 52.2%, p=0.001) when
classification was based on SCCmec type only. Comparison
with inclusion of pvl status showed a higher proportion of
chronic P. aeruginosa infection in patients with SCCmec-II
isolates compared to pvl-positive SCCmec-IV (p=0.004) but
not to pvl-negative SCCmec-IV (p=0.133); however sample
sizes are very small for the last comparison.Table 1
Background characteristics of MRSA positive patients overall and by SCCmec
status.
MRSA (n=82) SCCmec-II
(n=59)
SCCmec-IV,
pvl neg (n=9)
SCCmec-IV,
pvl pos (n=14)
All
Number (%) male 39 (47.6) 29 (50.8) 5 (55.5) 5 (35.7)
Age (years) a:
mean±SE
17.6±1.0 18.3±1.1 21.2±3.8 12.8±2.4
N (%)N18 years 34 (41.5) 26 (44.1) 5 (55.5) 4 (28.6)
P. aeruginosa 2005–2007: n (%)
Never 10 (12.2) 3 (5.1) 2 (22.2) 5 (35.7)
Intermittent 9 (11.0) 5 (8.5) 1 (11.1) 3 (21.4)
Chronic/mucoid 63 (76.8) 51(86.4) 6 (66.7) 6 (42.9)
a The date used for calculation of age was Aug. 1, 2007. For further
comparison of P. aeruginosa infection a group of MSSA infected patients was
used with same mean age, similar gender distribution (51.2% male) and 13.4%
never, 13.4% intermittent, and 73.6% chronic P. aeruginosa infection.3.2. Antimicrobial susceptibilities
Resistance to trimethoprim–sulfamethoxasole (TMP–SMX)
was low, both for initial isolates and those collected in 2007:
5.3% and 2.2% for SCCmec-II (n=52), 11.11% and 12.5%
among pvl-negative SCCmec-IV (n=8), and no resistance
among pvl-negative SCCmec-IV isolates (n=11). Clindamycin
resistance or inducible resistance was present in 98% of the
initial and 100% of subsequent SCCmec-II isolates. Again, pvl-
negative versus pvl-positive SCCmec-IV isolates differed:
62.5% of pvl-negative versus 7.1% and 33.3% of pvl-positive
isolates were clindamyin resistant at initial isolation and in
2007, respectively. Most MRSA isolates, regardless of
molecular type, were resistant to erythromycin (75–93%).
Resistance to gentamicin was low (0–11%) for all MRSA types,
except pvl-negative SCCmec-IV isolates 25% (2/8). No isolates
were reported indeterminate or resistant to vancomycin. Line-
zolid susceptibilities were not routinely evaluated.3.3. Treatment intensity and outcomes of patients with MRSA
compared to MSSA
As the different patient characteristics between MRSA types
may affect outcomes we compared the MRSA patients to an
age, gender, and P. aeruginosa matched cohort with MSSA to
test for differences in outcomes and treatments.
Cross-sectional comparisons of lung function using the best
measures in 2007, showed that mean FEV1 percent predicted was
75.1±2.7% among MRSA patients compared to 77.9±2.7%
among MSSA patients (p=0.486). Mean FEF25–75 percent
predicted was 60.9±4.3% versus 64.1±4.5% in MRSA and
MSSA patients, respectively (p=0.600). Similarly there was no
difference in nutritional status in 2007 as measured by BMI
percentile (41.3±3.4% for MRSA versus 41.0±3.1% for MSSA;
p=0.946). Patients with MRSA versus MSSA infection had a
similar number of exacerbations (2.4±0.2 versus 2.1±0.2;
p=0.186) and number of clinic visits (4.8±2.0 versus 4.9±0.3,
p=0.871) in 2006.
Pancreatic sufficiency (96% of MRSA and 90% in MSSA
p=0.212) and insulin dependent diabetes (6/82 in MSSA
compared to 12/82 MRSA (p=0.212) were similar. Chronic
pulmonary medications included use of tobramycin solution for
inhalation (TSI e.g. TOBI®), mucolytics (DNase and hyper-
tonic saline), inhaled steroids, and chronic oral azithromycin.
As shown in Table 2 there was a trend for higher use of chronic
medications in the MRSA patients for each of those medica-
tions, reaching significance for inhaled steroids and tobramycin
(p=0.003 and 0.008, respectively). Analysis of use of any of
these five medications showed that a higher proportion of
patients with MRSA were prescribed at least one of the five
pulmonary maintenance medications than patients with MSSA
(p=0.001). In the year prior to these measures patients with
MRSA received 72.2±6.1 days of oral and IV antibiotics for
exacerbations versus 61.2±4.8 in the MSSA group; p=0.157;
oral antibiotics only were: 52.2 ±5.4 versus 41.7 ±3.5;
p=0.091.
Table 2
Use of medications by MRSA and MSSA patients.
Medication use a MSSA n
(% of patients using med)
MRSA n
(% of patients using med)
P-value c
AZM 40 (48.8) 49 (59.8) 0.210
TSI 19 (23.2) 36 (43.9) 0.008
Hypertonic
saline
56 (68.3) 57 (69.5) 0.999
DNase 29 (35.3) 41 (50.0) 0.083
Inhaled steroids 29 (35.3) 49 (59.8) 0.003
Combined
meds. b
173 232 0.001
Enzymes 74 (90.2) 79 (96.3) 0.212
Diabetes
(insulin)
6 (7.3) 12 (14.6) 0.212
AZM=Azithromycin, TSI= tobramycin solution for inhalation.
a Use is categorized as Yes or No, and number and % of patients in each
group on the medication are counted.
b Combined medications represent the sum of five possible chronic
pulmonary medications used in each group. Maximum value would be 410.
c Chi-square for comparison of proportions; t-test for combined medications.
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As patients with MRSA were prescribed a more intense
medication regimen at the current time point but had similar
lung function we evaluated if either of these outcomes was
different prior to and after S. aureus infection. The linear rates
of change in FEV1 from one year prior to one year after
infection were −1.98% (±2.90%) per year and −2.81%
(±1.70%) for MSSA (n=43) and MRSA patients (n=62),
respectively. The difference in slopes between the two patient
groups was not statistically significant (p-value=0.805 after
adjusting for gender and age at infection) (Fig. 1). Similarly
there were no significant differences in linear rates of change in
BMI% across the two-year period surrounding infection for
patients with MRSA versus those with MSSA (p-value=0.310).
Age at initial staphylococcal infection was significantly
younger for MSSA than for MRSA patients (7.8±1.1 years
versus 13.3±1.1 years; p-valueb0.001).Fig. 1. Longitudinal rate of change in FEV1% during the 2 years surrounding the
infection with either MRSA (red) or MSSA (blue). Measurements obtained at 3-
month intervals were compared for one year pre-infection to one year
postinfection centered at the time of initial infection.Rates of decline before and after S. aureus infection are provided
in Fig. 2A (MSSA) and B (MRSA) for FEV1% predicted. The
models include an additional effect for change in FEV1 at the time
of infection, depicted as a solid dot on the graphs. For MRSA
patients, FEV1 is fairly flat during the months both before and after
infection but appears to drop notably at the time of infection;
however, this dropwas not statistically significant. No difference in
slopes for FEV1 before and after infectionwas detected (p-value for
difference in slopes = 0.874). For MSSA patients, FEV1 appears to
decline both before and after infection but increase somewhat at the
time of infection. This increase, however, was not statistically
significant, and no significant differences between the slopes before
and after infection were noted (p-value for difference in slopes =
0.754).4. Discussion
The current study characterizing MRSA in CF by molecular
typing of MRSA shows that demographic and clinical
characteristics differ among patients with SCCmec-II or
SCCmec-IV isolates. As described in the literature not all
SCCmec-IV isolates were pvl positive and these isolates were
associated with different clinical characteristics. Further
treatment details and outcomes of this population were
compared to a matched group of patients with MSSA.Fig. 2. Longitudinal change in FEV1 for MSSA (A) and MRSA (B) before and
after acquisition of S. aureus acquisition. Analysis focuses on differences in
rates of decline before and after S. aureus infection with an additional effect for
change at the time of initial acquisition.
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strain USA300 in the community. In our patient population we
find this MRSA strain in pediatric and adult patients.
Differentiation of MRSA types is relevant given the different
characteristics of community- versus hospital-associated
MRSA in non-CF patients. Differentiation based on epidemi-
ologic criteria is becoming difficult given the increasing number
of HA-MRSA patients with chronic diseases in the community
and outbreaks of CA-MRSA in the hospital [21,22]. Mutations
and genetic interchange between MRSA strains further
complicate molecular classification. Classification as CA-
versus HA-MRSA in fact may depend if epidemiologic,
SCCmec type, PVL status, or sensitivity to clindamycin is
used [23].
In this study we use primarily SCCmec typing but also
determine pvl status as USA300, the most frequent CA-MRSA
in the US, is pvl positive. Within SCCmec type IV six subtypes
have been described but not all of these are pvl positive, thus
PVL cannot be used as the sole criterion for definition as CA-
MRSA [24–26]. Our data show clinically relevant differences
between SCCmec types but also within SCCmec-IV depending
on pvl status in regard to demographic and clinical parameters,
and antimicrobial sensitivities. SCCmec-IV that were pvl
negative show the highest rate of resistance, e.g. an 11%
resistance to TMP–SMX in this group compared to 3–5% in all
other patients. This could indicate that these strains belong to
different SCCmec-IV subtypes or reflect the higher proportion
of adults with more use of antibiotics in this group.
Only two prior studies evaluated MRSA SCCmec types in
patients with CF [27]. These showed that approximately one-
third of MRSA strains recovered from CF patients were the
SCCmec type IV or V. Of these 29% were pvl positive, with a
higher rate among patients with recent MRSA acquisition [28].
None of our patients had suppurative lung disease as has been
described in cases of non-CF [29] and CF pneumonia [30].
A comparison of MRSA-positive patients to patients with
MSSA at our center matched for three main risk factors of worse
outcomes (age, gender, and P. aeruginosa) showed no difference
in cross-sectional comparison of lung function and nutrition
parameters. Use of chronic maintenance medications was higher
in MRSA-positive patients despite having comparable disease
severity. This could indicate that MRSA-positive patients require
more intensive therapy to maintain the same lung function as
MSSA-positive patients, a finding that would be consistent with
worse outcomes with MRSA as described by Ren et al. [6].
Neither use of antibiotics (either oral or all types of antibiotics) nor
frequency of exacerbations was different. Conceivably, MRSA-
positive patients may be sicker prior to the first isolation of this
organism. In fact we see a trend of having the lowest FEV1 at the
time of first MRSA. This explanation is consistent with the more
rapid decline prior to and after acquisition of MRSA versus
MSSA reported by Sawicki et al. [7]. In this scenarioMRSAmay
be a marker rather than a cause of worse disease. As MRSA
patients were older at the time of initial S. aureus infection than
those with MSSA, comparison of antibiotic use during the year
preceding infection is biased by other factors and was not done in
this study. Conceivably, medications may have been started priorto onset of MRSA infection and actually be risk factors for
development of resistance. The higher rate of nebulizer use or
inhaled steroids might be considered such potential risk factors.
Use of inhaled tobramycin as recommended for chronic
P. aeruginosa infection was higher among patients with MRSA
despite the same P. aeruginosa infection status, a finding
similar to a study evaluating impact of MRSA in patients
without P. aeruginosa where ~30% of patients with MSSA and
~60% with MRSA were on inhaled aminoglycosides [6,31].
We can only speculate on explanations for increased use of
inhaled aminoglycosides in MRSA positive patients; one,
patients with resistant organisms are considered sicker leading
to use of additional medications; two, that these patients had
prior P. aeruginosa and were continued on inhaled tobramycin.
Determination of the presence of P. aeruginosa prior to onset of
MRSA infection in the currently studied patients did not reveal
a systematic difference in frequency of P. aeruginosa infection
at the time of MRSA or MSSA onset (data not shown); three,
that high dose inhaled tobramycin is used in hopes of
eradicating MRSA, especially as N90% of strains are reported
as gentamicin susceptible in vitro. This approach would not be
appropriate as systemic aminoglycoside monotherapy is not
recommended for MRSA infection due to lack of efficacy.
Thus, inhaled tobramycin is unlikely to be effective for MRSA
as evident by the high number of patients who use inhaled high
dose tobramycin but continue to have MRSA in their sputum.
Our analyses of MRSA types are limited by the small sample
size, especially when evaluating pvl positive versus negative
SCCmec-IV types separately and did not allow for a
longitudinal study assessing therapies and concomitant infec-
tions. Another limitation is the retrospective data collection.
Given the current data and the increasing concern about MRSA
a larger and prospective study to evaluate outcomes based on
molecular MRSA typing is warranted and ongoing.
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